PEPTIDE COMPARISON

TB-500 vs GHK-Cu

Two recovery-market peptides compared by entity identity, route, and human evidence.

QUICK ANSWER

TB-500 vs GHK-Cu: the main difference.

Neither record supports a generic injectable recovery claim. TB-500 has a fundamental entity-transfer problem; GHK-Cu evidence varies substantially by route and outcome.

Decision field	TB-500	GHK-Cu
Human research	Very limited and often conflated with thymosin beta-4	Route-specific dermatologic and wound research
Primary research	Actin biology and tissue-repair models	Copper signaling, extracellular matrix, and skin research
FDA status	Not approved	No FDA-approved injectable GHK-Cu product identified
Identity problem	TB-500 is often treated as full-length thymosin beta-4	Topical findings are often transferred to injections
Evidence confidence	Very low for marketed recovery use	Route- and outcome-specific

SOURCES

TB-500 vs GHK-Cu sources.

WADA / 20262026 Prohibited ListWorld Anti-Doping Agency Review / 2015Thymosin beta-4 and tissue repairPubMed Human trial / 2006Topical copper tripeptide complex after carbon dioxide laser resurfacingPubMed FDA / 2026Pharmacy Compounding Advisory Committee meeting materialsU.S. FDA

TB-500 vs GHK-Cu: the main difference.

TB-500 vs GHK-Cu sources.

Questions related to TB-500 vs GHK-Cu.

Compare the next decision.